CDK17

Cyclin-dependent kinase 17

9,753 patent compounds predicted against CDK17, 7,785 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1661876	0.71	3/20
SCHEMBL1658928	0.69	3/20
SCHEMBL1660178	0.68	3/20
SCHEMBL1660111	0.63	3/20
SCHEMBL1659561	0.61	3/20
SCHEMBL1660265	0.56	3/20
Sorafenib (SCHEMBL8218)	1.00	2/20
Regorafenib (SCHEMBL432230)	1.00	2/20
Sorafenib (SCHEMBL1533976)	0.98	2/20
Sorafenib (SCHEMBL1533981)	0.98	2/20
Sorafenib (SCHEMBL1533982)	0.98	2/20
Sorafenib (SCHEMBL1896610)	0.98	2/20
Sorafenib (SCHEMBL1701746)	0.96	2/20
Sorafenib (SCHEMBL1702117)	0.96	2/20
Sorafenib (SCHEMBL1533972)	0.93	2/20
Sorafenib (SCHEMBL1534040)	0.93	2/20
Sorafenib (SCHEMBL1702369)	0.90	2/20
Sorafenib (SCHEMBL1702371)	0.90	2/20
SCHEMBL2024402	0.89	2/20
SCHEMBL1506380	0.86	2/20

Germline variants in CDK17 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDK17 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDK17 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.	PHASE2	COMPLETED
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation	PHASE2	ACTIVE_NOT_RECRUITING
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer	PHASE2	RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
A Clinical Study of TQB3824 in Subjects With Advanced Cancer	PHASE1	UNKNOWN
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)	PHASE1	COMPLETED
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors	PHASE1	COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors	PHASE1	COMPLETED
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer	PHASE1	NOT_YET_RECRUITING
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study	nan	ACTIVE_NOT_RECRUITING
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK17 binder may also engage these)

Protein	Name	Similarity
Q04899	—	1.000	Q04899 →
Q8K0D0	—	1.000	Q8K0D0 →
B0VXL7	—	1.000	B0VXL7 →
CDK14	Cyclin-dependent kinase 14	1.000	landscape →
O35831	—	1.000	O35831 →
Q9JLM8	—	0.999	Q9JLM8 →
O35495	—	0.999	O35495 →
O08875	—	0.998	O08875 →
Q63686	—	0.997	Q63686 →
P08458	—	0.996	P08458 →
C0RW22	—	0.996	C0RW22 →
Q21017	—	0.996	Q21017 →
P22204	—	0.996	P22204 →
Q66I46	—	0.996	Q66I46 →
RPS6KB1	Ribosomal protein S6 kinase beta-1	0.996	landscape →
P43289	—	0.996	P43289 →
Q40518	—	0.995	Q40518 →
Q9ZUZ2	—	0.995	Q9ZUZ2 →
O35832	—	0.995	O35832 →
CDK16	Cyclin-dependent kinase 16	0.995	landscape →
Q8BSK8	—	0.995	Q8BSK8 →
Q6TJY3	—	0.995	Q6TJY3 →
Q96287	—	0.995	Q96287 →
Q7YQL4	—	0.995	Q7YQL4 →
O23145	—	0.995	O23145 →
P43288	—	0.995	P43288 →
Q05512	—	0.995	Q05512 →
O44514	—	0.995	O44514 →
MARK2	Serine/threonine-protein kinase MARK2	0.994	landscape →
Q9TVL3	—	0.994	Q9TVL3 →